StocksFin Logo
ROIV logo
$ROIV

Roivant Sciences Ltd.

ROIV country of incorporation
|
|
863 employees
NASDAQ | Healthcare | Biotechnology
ROIV reported its Q323 earnings on February 13, 2023 (88 weeks ago).
$17.05M -29.9% vs. Q322 Revenues Q323
78.97% -16.3% vs. Q322 Gross Profit Margin
-1000% ! 0% vs. Q322 Net Profit Margin
-452.27M ! -266.6% vs. Q322 Free Cash Flow Q323
$-0.49 ! -19.5% vs. Q322 EPS Q323
Company Card Q323
As reported on February 13, 2023
Is profitable?
Has Revenue Growth?
Has Net Profit Growth?
Has FCF Growth?
Has OCF Growth?
Has EPS Growth?
Pays a Dividend?
Rating
B-
Growth calculated YoY
Company Card Q323
As reported on February 13, 2023
Is profitable?
Has Revenue Growth?
Has Net Profit Growth?
Has FCF Growth?
Has OCF Growth?
Has EPS Growth?
Pays a Dividend?
Rating
B-
Growth calculated YoY
Income Statement
Full Income Statement
Period Net Revenue Cost of Revenue Net Profit EPS
FY2023 Not reported yet.
Q32023
17.05M
+36.1%
3.59M
-352.01M
-20.7%
$-0.49
Q22023
12.53M
+190.2%
3.64M
-291.59M
+12.1%
$-0.42
Q12023
4.32M
1.73M
-331.81M
$-0.48
FY2022
55.29M
8.97M
-845.26M
$-1.26
Q42022
11.21M
+94.9%
517k
-69.67M
+73.3%
$-0.1
Q32022
24.34M
-76.4%
1.38M
-306.09M
+14.7%
$-0.41
Q32022
5.75M
+1739.8%
684k
-261.03M
-764.7%
$-0.38
Q22022
13.99M
6.38M
-208.48M
$-0.3
Q22022
1.32M
715k
-35.4M
$-0.05
Balance Sheet
Full Balance Sheet
Period Total Assets Total Liabilities Cash & Eq. Debt Stock Equity
FY2023 Not reported yet.
Q32023
2.2B
775.82M
1.53B
479.64M
955.52M
Q22023
2.22B
701.39M
1.6B
477.3M
1.16B
Q12023
2.6B
822.52M
1.94B
489.28M
1.38B
FY2022
2.59B
523.7M
2.06B
295.29M
1.66B
Cash Flow Statement
Full Cash Flow Statement
Period Operating CF Investing CF Financing CF Capex Free Cash Flow
FY2023 Not reported yet.
Q32023
-664.31M
-157.82M
289.13M
-11.07M
-675.37M
-49.3%
Q22023
-441.71M
-154.31M
134.64M
-10.56M
-452.27M
-74.3%
Q12023
-252.08M
-7.46M
141.98M
-7.46M
-259.54M
FY2022
-677.73M
303.3M
306.79M
-17.44M
-695.17M
Institutional Ownership
Dividend History
No dividend history.
Number of Employees